Table 1.
Patients’ characteristics
| Variable | RRP (N = 97) | HDR (N = 161) | Cryo (N = 114) | HIFU (N = 120) | P value |
|---|---|---|---|---|---|
| Age, years (mean ± SD) | 63.53 ± 6.71 | 71.92 ± 7.03 | 69.76 ± 6.49 | 68.06 ± 1.91 | 0.000 |
| Preoperative prostate volume, mL (mean ± SD) | 37.71 ± 16.97 | 37.48 ± 18.58 | 36.71 ± 16.94 | 21.97 ± 10.90 | 0.000 |
| iPSA, ng/mL (mean ± SD) | 16.08 ± 23.38 | 23.34 ± 20.40 | 26.76 ± 49.33 | 17.04 ± 21.88 | 0.002 |
| iPSA ≤ 10 ng/mL, N (%) | 40 (41.2) | 39 (24.2) | 39 (34.2) | 54 (45.0) | 0.000 |
| iPSA 10–20 ng/mL, N (%) | 37 (38.1) | 46 (28.6) | 39 (34.2) | 38 (31.7) | |
| iPSA ≥ 20 ng/mL, N (%) | 20 (20.6) | 76 (47.2) | 36 (31.6) | 28 (23.3) | |
| Gleason score | 0.002 | ||||
| ≤6, N (%) | 38 (39.2) | 82 (50.9) | 41 (36.0) | 36 (30.0) | |
| 7, N (%) | 41 (42.3) | 45 (28.0) | 38 (33.3) | 57 (47.5) | |
| ≥8, N (%) | 18 (18.6) | 34 (21.1) | 35 (30.7) | 27 (22.5) | |
| T stage | 0.000 | ||||
| <T2b, N (%) | 16 (16.5) | 26 (16.1) | 52 (45.6) | 73 (60.8) | |
| T2b, N (%) | 7 (7.2) | 34 (21.1) | 16 (14.0) | 14 (11.7) | |
| >T2b, N (%) | 74 (76.3) | 101 (62.7) | 46 (40.4) | 33 (27.5) | |
| D’Amico risk group | 0.000 | ||||
| Low, N (%) | 9 (9.3) | 6 (3.7) | 19 (16.7) | 15 (12.5) | |
| Intermediate, N (%) | 10 (10.3) | 32 (20.0) | 24 (21.1) | 47 (39.2) | |
| High, N (%) | 78 (80.4) | 123 (76.4) | 71 (62.3) | 58 (48.3) | |
| IIEF-5 ≥ 17, preoperative, N (%) | 38 (39.2) | 34 (21.1) | 50 (43.9) | 32 (26.7) | 0.000 |
| IIEF-5, preoperativea (mean ± SD) | 23.61 ± 2.13 | 22.88 ± 1.81 | 22.96 ± 2.44 | 22.10 ± 2.62 | 0.054 |
| IPSS, preoperative (mean ± SD) | 11.64 ± 8.84 | 8.51 ± 7.73 | 11.73 ± 7.53 | 10.16 ± 7.24 | 0.100 |
| QoL, preoperative (mean ± SD) | 3.60 ± 1.96 | 3.06 ± 2.01 | 3.11 ± 1.74 | 2.91 ± 1.69 | 0.266 |
RRP radical retropubic prostatectomy, HDR high dose rate brachytherapy, Cryo cryoablation, HIFU high-intensity focused ultrasound, SD standard deviation, iPSA initial prostate-specific antigen, IIEF-5 5-item version of the international index of erectile function, IPSS international prostate symptom score, QoL quality of life
aMean scores for IIEF-5 were restricted to those men who reported IIEF-5 ≥ 17 at baseline